FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2992413915> ?p ?o ?g. }

• W2992413915 endingPage "72" @default.
• W2992413915 startingPage "64" @default.
• W2992413915 abstract "ABSTRACT Introduction Turoctocog alfa is a recombinant, B domain‐truncated factor VIII (FVIII) approved for patients with haemophilia A. Aim To evaluate the safety and efficacy of turoctocog alfa in previously untreated patients (PUPs) with severe haemophilia A. Methods Guardian 4 was a multicentre, multinational, non‐randomized, open‐label phase 3 trial comprising a main and extension phase. The former concluded once ≥ 50 patients had received treatment for ≥ 50 exposure days (EDs) or developed inhibitors. Patients received turoctocog alfa intravenously for prevention and treatment of bleeds. The primary endpoint was the incidence rate of FVIII inhibitors (≥0.6 Bethesda Units) reported during the first 50 EDs. Results Of the 58 patients who completed the main phase, 25 (43.1%) patients developed inhibitors (detected within 6‐24 [mean: 14.2] EDs from treatment start). High‐risk mutations were identified in 60% of patients who developed inhibitors in the main phase and were a significant predictor of inhibitor development ( P = .003). Of the 21 patients who started immune tolerance induction therapy, 85.7% completed treatment with a negative inhibitor test (note that data on the last 3 patients completing ITI are based on information collated from sites prior to the final database lock). Haemostatic response (including missing values as failure) was rated as ‘excellent’ or ‘good’ for 86.1% of bleeds occurring during prophylaxis. The estimated mean annualized bleeding rate for patients on prophylaxis was 4.26 bleeds/patient/year (95% CI: 3.34 − 5.44). Conclusions Turoctocog alfa was effective at preventing and stopping bleeds and was well tolerated. Inhibitor development was within the expected range for this PUP population." @default.
• W2992413915 created "2019-12-13" @default.
• W2992413915 creator A5008729352 @default.
• W2992413915 creator A5016760314 @default.
• W2992413915 creator A5018291401 @default.
• W2992413915 creator A5047434427 @default.
• W2992413915 creator A5050723834 @default.
• W2992413915 creator A5054089330 @default.
• W2992413915 creator A5063402602 @default.
• W2992413915 creator A5070244247 @default.
• W2992413915 creator A5085306795 @default.
• W2992413915 creator A5091197819 @default.
• W2992413915 date "2019-12-09" @default.
• W2992413915 modified "2023-10-02" @default.
• W2992413915 title "Safety and efficacy of turoctocog alfa in the prevention and treatment of bleeds in previously untreated paediatric patients with severe haemophilia A: Results from the guardian 4 multinational clinical trial" @default.
• W2992413915 cites W1896702999 @default.
• W2992413915 cites W1963967196 @default.
• W2992413915 cites W1976302929 @default.
• W2992413915 cites W1977385644 @default.
• W2992413915 cites W1980979476 @default.
• W2992413915 cites W1991223023 @default.
• W2992413915 cites W1997223335 @default.
• W2992413915 cites W1997760245 @default.
• W2992413915 cites W2013607072 @default.
• W2992413915 cites W2027157500 @default.
• W2992413915 cites W2033176757 @default.
• W2992413915 cites W2038167434 @default.
• W2992413915 cites W2085306050 @default.
• W2992413915 cites W2088014761 @default.
• W2992413915 cites W2099134690 @default.
• W2992413915 cites W2128487729 @default.
• W2992413915 cites W2131061927 @default.
• W2992413915 cites W2147887043 @default.
• W2992413915 cites W2156757766 @default.
• W2992413915 cites W2163909723 @default.
• W2992413915 cites W2168608087 @default.
• W2992413915 cites W2170563066 @default.
• W2992413915 cites W2239768358 @default.
• W2992413915 cites W2337290468 @default.
• W2992413915 cites W2401865216 @default.
• W2992413915 cites W2748331328 @default.
• W2992413915 cites W2766390816 @default.
• W2992413915 cites W2792416539 @default.
• W2992413915 cites W2792993637 @default.
• W2992413915 cites W2793075683 @default.
• W2992413915 cites W2794460969 @default.
• W2992413915 cites W2899796162 @default.
• W2992413915 cites W4250654072 @default.
• W2992413915 cites W4255839272 @default.
• W2992413915 doi "https://doi.org/10.1111/hae.13883" @default.
• W2992413915 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7028046" @default.
• W2992413915 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/31816159" @default.
• W2992413915 hasPublicationYear "2019" @default.
• W2992413915 type Work @default.
• W2992413915 sameAs 2992413915 @default.
• W2992413915 citedByCount "12" @default.
• W2992413915 countsByYear W29924139152020 @default.
• W2992413915 countsByYear W29924139152021 @default.
• W2992413915 countsByYear W29924139152022 @default.
• W2992413915 countsByYear W29924139152023 @default.
• W2992413915 crossrefType "journal-article" @default.
• W2992413915 hasAuthorship W2992413915A5008729352 @default.
• W2992413915 hasAuthorship W2992413915A5016760314 @default.
• W2992413915 hasAuthorship W2992413915A5018291401 @default.
• W2992413915 hasAuthorship W2992413915A5047434427 @default.
• W2992413915 hasAuthorship W2992413915A5050723834 @default.
• W2992413915 hasAuthorship W2992413915A5054089330 @default.
• W2992413915 hasAuthorship W2992413915A5063402602 @default.
• W2992413915 hasAuthorship W2992413915A5070244247 @default.
• W2992413915 hasAuthorship W2992413915A5085306795 @default.
• W2992413915 hasAuthorship W2992413915A5091197819 @default.
• W2992413915 hasBestOaLocation W29924139151 @default.
• W2992413915 hasConcept C120665830 @default.
• W2992413915 hasConcept C121332964 @default.
• W2992413915 hasConcept C126322002 @default.
• W2992413915 hasConcept C141071460 @default.
• W2992413915 hasConcept C168563851 @default.
• W2992413915 hasConcept C187212893 @default.
• W2992413915 hasConcept C197934379 @default.
• W2992413915 hasConcept C203092338 @default.
• W2992413915 hasConcept C2777232031 @default.
• W2992413915 hasConcept C2778385053 @default.
• W2992413915 hasConcept C535046627 @default.
• W2992413915 hasConcept C61511704 @default.
• W2992413915 hasConcept C71924100 @default.
• W2992413915 hasConceptScore W2992413915C120665830 @default.
• W2992413915 hasConceptScore W2992413915C121332964 @default.
• W2992413915 hasConceptScore W2992413915C126322002 @default.
• W2992413915 hasConceptScore W2992413915C141071460 @default.
• W2992413915 hasConceptScore W2992413915C168563851 @default.
• W2992413915 hasConceptScore W2992413915C187212893 @default.
• W2992413915 hasConceptScore W2992413915C197934379 @default.
• W2992413915 hasConceptScore W2992413915C203092338 @default.
• W2992413915 hasConceptScore W2992413915C2777232031 @default.
• W2992413915 hasConceptScore W2992413915C2778385053 @default.
• W2992413915 hasConceptScore W2992413915C535046627 @default.
• W2992413915 hasConceptScore W2992413915C61511704 @default.
• W2992413915 hasConceptScore W2992413915C71924100 @default.

• next